[1]王雪,张真稳.钠-葡萄糖共转运蛋白2抑制剂对糖尿病相关眼病的影响[J].国际内分泌代谢杂志,2024,44(03):198-201.[doi:10.3760/cma.j.cn121383-20230619-06036]
　Wang Xue,Zhang Zhenwen..Effects of sodium-glucose cotransporter 2 inhibitors on ocular diseases in patients with diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2024,44(03):198-201.[doi:10.3760/cma.j.cn121383-20230619-06036]
点击复制

钠-葡萄糖共转运蛋白2抑制剂对糖尿病相关眼病的影响 ()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
44
期数:
2024年03期
页码:
198-201
栏目:
综述
出版日期:
2024-05-20

文章信息/Info

Title:
Effects of sodium-glucose cotransporter 2 inhibitors on ocular diseases in patients with diabetes mellitus
作者:
王雪; 张真稳
扬州大学附属苏北人民医院,扬州 225000
Author(s):
Wang Xue;  Zhang Zhenwen.
Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225000, China.
关键词:
钠-葡萄糖共转运蛋白2抑制剂;  糖尿病性视网膜病变;  糖尿病性白内障;  糖尿病性角膜病变
Keywords:
Sodium-Glucose Transporter 2 Inhibitors;  Diabetic Retinopathy;  Diabetic Cataract;  Diabetic Keratopathy
DOI:
10.3760/cma.j.cn121383-20230619-06036
摘要:
眼是糖尿病主要损害的靶器官之一,糖尿病相关眼病是一组严重影响患者视觉质量乃至致盲的疾病。目前的临床治疗大多适用于眼病晚期,亟需相关防治眼病发生发展的药物。钠-葡萄糖共转运蛋白2抑制剂(SGLT2i)是用于降低糖尿病患者高血糖的新型口服药物,在糖尿病相关性心血管和肾脏疾病已表现出高度有益作用。目前,利用SGLT2i降低血糖同时防治糖尿病相关眼部疾病也成为一个新的研究领域。本文主要综述了SGLT2i在糖尿病相关眼部疾病的研究进展。
Abstract:
The eye is one of the major target organs damaged by diabetes, and diabetes-related eye diseases are a group of diseases that seriously affect the quality of vision of patients and even cause blindness. Most of the current clinical treatments are applicable to the advanced stages of eye disease, and there is an urgent need for drugs to prevent the development of eye disease. Sodium-Glucose Transporter 2 Inhibitors(SGLT2i)are novel oral drugs used to reduce hyperglycaemia in diabetic patients, and have shown highly beneficial effects in diabetes-associated cardiovascular and renal diseases. Currently, the use of SGLT2i to lower blood glucose while preventing diabetes-associated eye diseases has also become a new area of research. This article mainly reviews the research progress of SGLT2i in diabetes-related eye diseases.

参考文献/References:

[1] 中华医学会糖尿病学分会视网膜病变学组.糖尿病相关眼病防治多学科中国专家共识(2021年版)[J].中华糖尿病杂志,2021,13(11):1026-1042.DOI:10.3760/cma.j.cn115791-20211006-00534.
[2] Wakisaka M,Nagao T,Yoshinari M.Sodium glucose cotransporter 2(SGLT2)plays as a physiological glucose sensor and regulates cellular contractility in rat mesangial cells[J].PloS One2016,11(3):e0151585.DOI:10.1371/journal.pone.0151585.
[3] Hu Y,Xu Q,Li H,et al.Dapagliflozin reduces apoptosis of diabetic retina and human retinal microvascular endothelial cells through ERK1/2/cPLA2/AA/ROS pathway independent of hypoglycemic[J].Frontiers in Pharmacology,2022,13:827896.DOI:10.3389/fphar.2022.827896.
[4] Sabaner MC,Duman R,Dogan M,et al.Do SGLT2 inhibitors prevent preclinical diabetic retinopathy?A prospective pilot optical coherence tomography angiography study[J].J Fr Ophtalmol,2021,44(8):1159-1167.DOI:10.1016/j.jfo.2021.01.005.
[5] Yen FS,Wei JC,Yu TS,et al.Sodium-glucose cotransporter 2 inhibitors and risk of retinopathy in patients with type 2 diabetes[J].JAMA Netw Open,2023,6(12):e2348431.DOI:10.1001/jamanetworkopen.2023.48431.
[6] Takatsuna Y,Ishibashi R,Tatsumi T,et al.Sodium glucose cotransporter 2 inhibitors improve chronic diabetic macular edema[J].Case Rep Ophthalmol Med,2020,2020:8867079.DOI:10.1155/2020/8867079.
[7] Ma Y,Lin C,Cai X,et al.The association between the use of sodium glucose cotransporter 2 inhibitor and the risk of diabetic retinopathy and other eye disorders:a systematic review and meta-analysis[J].Expert Rev Clin Pharmacol,2022,15(7):877-886.DOI:10.1080/17512433.2022.2102973.
[8] Hu WS, Lin CL.Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use and cataract risk:real-world observational investigation[J].Acta Diabetol,2023,60(7):981-987.DOI:10.1007/s00592-023-02087-y.
[9] Takakura S,Toyoshi T,Hayashizaki Y,et al.Effect of ipragliflozin,an SGLT2 inhibitor,on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats[J].Life Sci,2016,147:125-131.DOI:10.1016/j.lfs.2016.01.042.
[10] Chen YY,Chen CK,Wu TT,et al.Attenuation of epithelial-mesenchymal transition via SGLT2 inhibition and diabetic cataract suppression by dapagliflozin nanoparticles treatment[J].Life Sci,2023,330:122005.DOI:10.1016/j.lfs.2023.122005.
[11] Yao YP,Yang PJ,Lee CY,et al.Utilization of sodium-glucose cotransporter 2 inhibitors on dry eye disease severity in patients with type 2 diabetes mellitus[J].Int J Med Sci,2023,20(13):1705-1710.DOI:10.7150/ijms.88720.
[12] Tsai TY,Yang PJ,Chao SC,et al.Association of sodium-glucose cotransporter 2 inhibitors with the incidence of corneal diseases in type 2 diabetes mellitus[J].Int J Med Sci,2024,21(3):583-592.DOI:10.7150/ijms.91571.
[13] Li C,Zhou Z,Neuen BL,et al.Sodium-glucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes:a systematic review and meta-analysis[J].Diabetes Obes Metab,2021,23(1):252-257.DOI:10.1111/dom.14197.
[14] Zhou B,Shi Y,Fu R,et al.Relationship between SGLT-2i and ocular diseases in patients with type 2 diabetes mellitus:a meta-analysis of randomized controlled trials[J].Front Endocrinol(Lausanne),2022,13:907340.DOI:10.3389/fendo.2022.907340.
[15] Ott C,Jumar A,Striepe K,et al.A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation[J].Cardiovascular diabetology,2017,16(1):26.DOI:10.1186/s12933-017-0510-1.
[16] Simó-servat O,Simó R,Hernández C.Circulating biomarkers of diabetic retinopathy:an overview based on physiopathology[J].J Diabetes Res,2016,2016:5263798.DOI:10.1155/2016/5263798.
[17] Hanaguri J,Yokota H,Kushiyama A,et al.The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice[J].Int J Mol Sci2022,23(3):1362.DOI:10.3390/ijms23031362.
[18] Xu L,Nagata N,Nagashimada M,et al.SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing m2 macrophages in diet-induced obese mice[J].EBioMedicine,2017,20:137-149.DOI:10.1016/j.ebiom.2017.05.028.
[19] Lee N,Heo YJ,Choi SE,et al.Anti-inflammatory effects of empagliflozin and gemigliptin on lps-stimulated macrophage via the IKK/NF-κB, MKK7/JNK,and JAK2/STAT1 signalling pathways[J].J Immunol Res,2021,2021:9944880.DOI:10.1155/2021/9944880.
[20] Mudaliar S,Hupfeld C,Chao DL.SGLT2 inhibitor-induced low-grade ketonemia ameliorates retinal hypoxia in diabetic retinopathy-a novel hypothesis[J]. J Clin Endocrinol Metab,2021,106(5):1235-1244.DOI:10.1210/clinem/dgab050.
[21] Herat LY,Matthews VB,Rakoczy PE,et al.Focusing on sodium glucose cotransporter-2 and the sympathetic nervous system:potential impact in diabetic retinopathy[J].Int J Endocrinol,2018,2018:9254126.DOI:10.1155/2018/9254126.
[22] Hanaguri J,Yokota H,Kushiyama A,et al.The effect of sodium-dependent glucose cotransporter 2 inhibitor tofogliflozin on neurovascular coupling in the retina in type 2 diabetic mice[J].Int J Mol Sci,2022,23(3):1362.DOI:10.3390/ijms23031362.
[23] Herat lY,Matthews JR,Ong WE,et al.Determining the role of SGLT2 inhibition with dapagliflozin in the development of diabetic retinopathy[J].Front Biosci(Landmark Ed),2022,27(12):321.DOI:10.31083/j.fbl2712321.
[24] Matthews J,Herat L,Rooney J,et al.Determining the role of SGLT2 inhibition with empagliflozin in the development of diabetic retinopathy[J].Biosci Rep,2022,42(3):BSR20212209.DOI:10.1042/BSR20212209.

相似文献/References:

[1]廖英宏,庄晓婷,白越,等.钠-葡萄糖共转运蛋白2抑制剂在血管衰老中的作用[J].国际内分泌代谢杂志,2022,42(05):373.[doi:10.3760/cma.j.cn121383-20210715-07038]
　Liao Yinghong,Zhuang Xiaoting,Bai Yue,et al.Roles of sodium glucose cotransporter 2 inhibitor in vascular aging[J].International Journal of Endocrinology and Metabolism,2022,42(03):373.[doi:10.3760/cma.j.cn121383-20210715-07038]
[2]《钠-葡萄糖共转运蛋白抑制剂联合二甲双胍治疗型糖尿病专家共识》专家组.钠-葡萄糖共转运蛋白2抑制剂联合二甲双胍治疗2型糖尿病专家共识[J].国际内分泌代谢杂志,2023,43(05):437.[doi:10.3760/cma.j.cn121383-20230725-07036]
　Expert Group for Expert Consensus on Sodium-Glucose Cotransporter- Inhibitors with Metformin in Patients with Type Diabetes Mellitus.Expert consensus on sodium-glucose cotransporter-2 inhibitors with metformin in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2023,43(03):437.[doi:10.3760/cma.j.cn121383-20230725-07036]

备注/Memo

备注/Memo:
通信作者:张真稳,Email:yzdxzzw@163.com
基金项目:江苏省中医药科技发展计划项目(YB2020087); 国家自然科学基金项目82374100)
更新日期/Last Update: 2024-05-30